PPBT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States...

Stats
Today's Volume	103 386
Average Volume	154 693
Market Cap	15.19M
EPS	$0 ( 2024-03-06 )
Next earnings date	( $-0.150 ) 2024-05-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.00900 (1.70%)

Volume Correlation

Long: -0.35 (neutral)

Short: -0.67 (moderate negative)

Signal:(41.919) Neutral

Purple Biotech Ltd. Correlation

10 Most Positive Correlations
HALL	0.893
SNCR	0.877
NEXT	0.864
SBUX	0.862
LMNL	0.855
MTEK	0.833
NVIV	0.832
AYRO	0.827
RMRM	0.817
WTFC	0.817

10 Most Negative Correlations
BNIXU	-0.942
BLZE	-0.872
ARTNA	-0.868
DOYU	-0.863
ACST	-0.852
FNKO	-0.844
ANZU	-0.841
CAMP	-0.832
CXSE	-0.831
WTBA	-0.829

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Purple Biotech Ltd. Correlation - Currency/Commodity

-0.27
( neutral )

-0.02
( neutral )

0.00
( neutral )

-0.09
( neutral )

Purple Biotech Ltd. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-199 000 (0.00 %)
EPS:	$-0.810

FY	2023
Revenue:	$0
Gross Profit:	$-199 000 (0.00 %)
EPS:	$-0.810

FY	2022
Revenue:	$-910 000
Gross Profit:	$-1.11M (122.09 %)
EPS:	$-1.130

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.050

Financial Reports:

No articles found.

Purple Biotech Ltd.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.